UBS O'Connor’s AtriCure ATRC Stock Holding History

UBS O'Connor’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,199	Closed	-$435K	–	523
2023 Q4	$435K	Sell	12,199 -37,094	-75%	-$1.38M	0.01%	367
2023 Q3	$2.16M	Buy	49,293 +9,000	+22%	+$439K	0.04%	234
2023 Q2	$1.99M	Sell	40,293 -867	-2%	-$40K	0.04%	291
2023 Q1	$1.71M	Buy	+41,160	New	+$1.71M	0.04%	350
2022 Q4	–	Sell	-12,300	Closed	-$481K	–	39
2022 Q3	$481K	Buy	+12,300	New	+$563K	0.01%	813
2015 Q3	–	Sell	-25,000	Closed	-$616K	–	510
2015 Q2	$616K	Sell	25,000 -15,000	-38%	-$335K	0.01%	517
2015 Q1	$820K	Sell	40,000 -20,000	-33%	-$387K	0.02%	434
2014 Q4	$1.2M	Hold	60,000	–	–	0.02%	337
2014 Q3	$883K	Buy	60,000 +20,000	+50%	+$319K	0.02%	358
2014 Q2	$735K	Sell	40,000 -10,000	-20%	-$166K	﹤0.01%	349
2014 Q1	$940K	Buy	+50,000	New	+$1.02M	0.02%	329

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's ATRC Position: Q1 2024 in Review

UBS O'Connor sold out of AtriCure (ATRC) in Q1 2024, closing a stake of 12,199 shares — an estimated $435K sold.

UBS O'Connor first reported a position in ATRC in Q1 2014 and held it in 11 quarters. The position peaked at $2.16M in Q3 2023. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2024.

UBS O'Connor reported no remaining AtriCure position as of Q1 2024 after selling out during the quarter.
UBS O'Connor sold 12,199 AtriCure shares in Q1 2024, an estimated $435K.
UBS O'Connor first reported a position in AtriCure in Q1 2014 and held it in 11 quarters.
UBS O'Connor's AtriCure position peaked at $2.16M in Q3 2023.
224 funds tracked by Wall St. Rank held AtriCure as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.